Erythromycin Drug Interactions
265Total Interactions
170Severe
90Moderate
5Mild
| Drug | Severity | Summary |
|---|---|---|
| Acalabrutinib | SEVERE | Erythromycin is predicted to increase the exposure to Acalabrutinib. Manufacturer advises avoid o... |
| Acenocoumarol | SEVERE | Erythromycin increases the anticoagulant effect of Acenocoumarol. Manufacturer advises monitor IN... |
| Alprazolam | SEVERE | Erythromycin is predicted to increase the exposure to Alprazolam. Manufacturer advises caution. |
| Amifampridine | SEVERE | Both Erythromycin and Amifampridine prolong the QT interval. Most manufacturers advise avoiding t... |
| Aminophylline | SEVERE | Aminophylline is predicted to decrease the exposure to Erythromycin. Manufacturer advises adjust ... |
| Amiodarone | SEVERE | Both Erythromycin and Amiodarone prolong the QT interval. Most manufacturers advise avoiding the ... |
| Amisulpride | SEVERE | Both Erythromycin and Amisulpride prolong the QT interval. Most manufacturers advise avoiding the... |
| Amphotericin B | SEVERE | Amphotericin B is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Anagrelide | SEVERE | Both Erythromycin and Anagrelide prolong the QT interval. Most manufacturers advise avoiding the ... |
| Apalutamide | SEVERE | Both Erythromycin and Apalutamide prolong the QT interval. Most manufacturers advise avoiding the... |
| Apomorphine | SEVERE | Both Erythromycin and Apomorphine prolong the QT interval. Most manufacturers advise avoiding the... |
| Aripiprazole | SEVERE | Both Erythromycin and Aripiprazole prolong the QT interval. Most manufacturers advise avoiding th... |
| Arsenic trioxide | SEVERE | Both Erythromycin and Arsenic trioxide prolong the QT interval. Most manufacturers advise avoidin... |
| Artemether | SEVERE | Both Erythromycin and Artemether prolong the QT interval. Most manufacturers advise avoiding the ... |
| Artenimol | SEVERE | Both Erythromycin and Artenimol prolong the QT interval. Most manufacturers advise avoiding the u... |
| Atazanavir | SEVERE | Atazanavir is predicted to increase the exposure to Erythromycin. Manufacturer makes no recommend... |
| Atorvastatin | SEVERE | Erythromycin slightly increases the exposure to Atorvastatin. Manufacturer advises monitor and ad... |
| Beclometasone | SEVERE | Beclometasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Bedaquiline | SEVERE | Both Erythromycin and Bedaquiline prolong the QT interval. Most manufacturers advise avoiding the... |
| Bendroflumethiazide | SEVERE | Bendroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Betamethasone | SEVERE | Betamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Bosutinib | SEVERE | Erythromycin is predicted to increase the exposure to Bosutinib. Manufacturer advises avoid or ad... |
| Brentuximab vedotin | SEVERE | Erythromycin increases the risk of neutropenia when given with Brentuximab vedotin. Manufacturer ... |
| Bromocriptine | SEVERE | Erythromycin is predicted to increase the exposure to Bromocriptine. Manufacturer makes no recomm... |
| Budesonide | SEVERE | Budesonide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Bumetanide | SEVERE | Bumetanide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Cabergoline | SEVERE | Erythromycin is predicted to increase the concentration of Cabergoline. Manufacturer advises avoid. |
| Cabozantinib | SEVERE | Both Erythromycin and Cabozantinib prolong the QT interval. Most manufacturers advise avoiding th... |
| Carbamazepine | SEVERE | Erythromycin markedly increases the concentration of Carbamazepine. Manufacturer advises monitor ... |
| Cariprazine | SEVERE | Erythromycin is predicted to increase the exposure to Cariprazine. Manufacturer advises monitor a... |
| Ceritinib | SEVERE | Both Erythromycin and Ceritinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Chloroquine | SEVERE | Erythromycin might increase the risk of serious cardiovascular adverse effects when given with Ch... |
| Chlorothiazide | SEVERE | Chlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Chlorpromazine | SEVERE | Both Erythromycin and Chlorpromazine prolong the QT interval. Most manufacturers advise avoiding ... |
| Chlortalidone | SEVERE | Chlortalidone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Ciclosporin | SEVERE | Erythromycin greatly increases the exposure to Ciclosporin. Manufacturer advises avoid or monitor. |
| Citalopram | SEVERE | Both Erythromycin and Citalopram prolong the QT interval. Most manufacturers advise avoiding the ... |
| Clomipramine | SEVERE | Both Erythromycin and Clomipramine prolong the QT interval. Most manufacturers advise avoiding th... |
| Clozapine | SEVERE | Erythromycin potentially increases the risk of toxicity when given with Clozapine. Manufacturer a... |
| Cobimetinib | SEVERE | Erythromycin is predicted to increase the exposure to Cobimetinib. Manufacturer advises caution a... |
| Colchicine | SEVERE | Erythromycin is predicted to increase the exposure to Colchicine. Manufacturer advises adjust Col... |
| Crizotinib | SEVERE | Both Erythromycin and Crizotinib prolong the QT interval. Most manufacturers advise avoiding the ... |
| Dabigatran | SEVERE | Erythromycin is predicted to increase the exposure to Dabigatran. Manufacturer makes no recommend... |
| Daridorexant | SEVERE | Erythromycin is predicted to increase the exposure to Daridorexant. Manufacturer advises adjust D... |
| Darunavir | SEVERE | Darunavir is predicted to increase the exposure to Erythromycin. Manufacturer advises caution and... |
| Dasatinib | SEVERE | Erythromycin is predicted to increase the exposure to Dasatinib. Manufacturer makes no recommenda... |
| Deflazacort | SEVERE | Deflazacort is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Delamanid | SEVERE | Both Erythromycin and Delamanid prolong the QT interval. Most manufacturers advise avoiding the u... |
| Desflurane | SEVERE | Both Erythromycin and Desflurane prolong the QT interval. Most manufacturers advise avoiding the ... |
| Deutivacaftor | SEVERE | Erythromycin is predicted to increase the exposure to Deutivacaftor. Manufacturer advises adjust ... |
| Dexamethasone | SEVERE | Dexamethasone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Digoxin | SEVERE | Erythromycin increases the concentration of Digoxin. Manufacturer advises monitor Digoxin concent... |
| Diltiazem | SEVERE | Erythromycin is predicted to increase the exposure to Diltiazem. Manufacturer makes no recommenda... |
| Disopyramide | SEVERE | Both Erythromycin and Disopyramide prolong the QT interval. Most manufacturers advise avoiding th... |
| Docetaxel | SEVERE | Erythromycin is predicted to increase the exposure to Docetaxel. Manufacturer makes no recommenda... |
| Domperidone | SEVERE | Erythromycin is predicted to increase the exposure to Domperidone. Manufacturer advises avoid. |
| Dronedarone | SEVERE | Erythromycin is predicted to moderately increase the exposure to Dronedarone. Manufacturer advise... |
| Droperidol | SEVERE | Both Erythromycin and Droperidol prolong the QT interval. Most manufacturers advise avoiding the ... |
| Drospirenone | SEVERE | Erythromycin is predicted to increase the exposure to Drospirenone. Manufacturer makes no recomme... |
| Efavirenz | SEVERE | Both Erythromycin and Efavirenz prolong the QT interval. Most manufacturers advise avoiding the u... |
| Elacestrant | SEVERE | Erythromycin is predicted to increase the exposure to Elacestrant. Manufacturer advises avoid mod... |
| Elexacaftor | SEVERE | Erythromycin is predicted to increase the exposure to Elexacaftor. Manufacturer advises adjust iv... |
| Eliglustat | SEVERE | Erythromycin is predicted to increase the exposure to Eliglustat. Manufacturer advises avoid or a... |
| Encorafenib | SEVERE | Both Erythromycin and Encorafenib prolong the QT interval. Most manufacturers advise avoiding the... |
| Entrectinib | SEVERE | Erythromycin is predicted to increase the exposure to Entrectinib. Manufacturer advises avoid or ... |
| Eplerenone | SEVERE | Erythromycin is predicted to increase the exposure to Eplerenone. Manufacturer advises adjust Epl... |
| Ergometrine | SEVERE | Erythromycin is predicted to increase the risk of ergotism when given with Ergometrine. Manufactu... |
| Eribulin | SEVERE | Both Erythromycin and Eribulin prolong the QT interval. Most manufacturers advise avoiding the us... |
| Escitalopram | SEVERE | Both Erythromycin and Escitalopram prolong the QT interval. Most manufacturers advise avoiding th... |
| Etrasimod | SEVERE | Erythromycin is predicted to increase the exposure to Etrasimod. Manufacturer advises avoid in po... |
| Finerenone | SEVERE | Erythromycin is predicted to increase the exposure to Finerenone. Manufacturer advises monitor. |
| Fingolimod | SEVERE | Fingolimod might increase the risk of QT-prolongation when given with Erythromycin. Manufacturer ... |
| Fluconazole | SEVERE | Both Erythromycin and Fluconazole prolong the QT interval. Most manufacturers advise avoiding the... |
| Fludrocortisone | SEVERE | Fludrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de... |
| Formoterol | SEVERE | Formoterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Fosamprenavir | SEVERE | Fosamprenavir is predicted to increase the exposure to Erythromycin. Manufacturer advises caution... |
| Furosemide | SEVERE | Furosemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Glasdegib | SEVERE | Both Erythromycin and Glasdegib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Granisetron | SEVERE | Granisetron is predicted to increase the risk of QT-prolongation when given with Erythromycin. Ma... |
| Haloperidol | SEVERE | Both Erythromycin and Haloperidol prolong the QT interval. Most manufacturers advise avoiding the... |
| Hydrochlorothiazide | SEVERE | Hydrochlorothiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsad... |
| Hydrocortisone | SEVERE | Hydrocortisone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de ... |
| Hydroflumethiazide | SEVERE | Hydroflumethiazide is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Hydroxychloroquine | SEVERE | Erythromycin might increase the risk of serious cardiovascular adverse effects when given with Hy... |
| Hydroxyzine | SEVERE | Both Erythromycin and Hydroxyzine prolong the QT interval. Most manufacturers advise avoiding the... |
| Ibrutinib | SEVERE | Erythromycin is predicted to increase the exposure to Ibrutinib. Manufacturer advises adjust dose... |
| Indacaterol | SEVERE | Indacaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Indapamide | SEVERE | Indapamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Inotuzumab ozogamicin | SEVERE | Both Erythromycin and Inotuzumab ozogamicin prolong the QT interval. Most manufacturers advise av... |
| Isoflurane | SEVERE | Both Erythromycin and Isoflurane prolong the QT interval. Most manufacturers advise avoiding the ... |
| Isoprenaline | SEVERE | Isoprenaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Ivabradine | SEVERE | Ivabradine is predicted to increase the risk of torsade de pointes when given with Erythromycin. ... |
| Ivosidenib | SEVERE | Erythromycin is predicted to increase the exposure to Ivosidenib. Manufacturer advises monitor an... |
| Lapatinib | SEVERE | Both Erythromycin and Lapatinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Lenvatinib | SEVERE | Both Erythromycin and Lenvatinib prolong the QT interval. Most manufacturers advise avoiding the ... |
| Levomepromazine | SEVERE | Both Erythromycin and Levomepromazine prolong the QT interval. Most manufacturers advise avoiding... |
| Lopinavir | SEVERE | Lopinavir is predicted to increase the exposure to Erythromycin. Manufacturer advises caution. |
| Mefloquine | SEVERE | Mefloquine is predicted to increase the risk of QT-prolongation when given with Erythromycin. Man... |
| Methadone | SEVERE | Both Erythromycin and Methadone prolong the QT interval. Most manufacturers advise avoiding the u... |
| Methylprednisolone | SEVERE | Methylprednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade... |
| Metolazone | SEVERE | Metolazone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Midazolam | SEVERE | Erythromycin is predicted to increase the exposure to Midazolam. Manufacturer advises monitor adv... |
| Mizolastine | SEVERE | Erythromycin is predicted to increase the exposure to Mizolastine. Manufacturer advises caution. |
| Moxifloxacin | SEVERE | Both Erythromycin and Moxifloxacin prolong the QT interval. Most manufacturers advise avoiding th... |
| Neratinib | SEVERE | Erythromycin is predicted to increase the exposure to Neratinib. Manufacturer advises avoid moder... |
| Nilotinib | SEVERE | Both Erythromycin and Nilotinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Olodaterol | SEVERE | Olodaterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Ondansetron | SEVERE | Both Erythromycin and Ondansetron prolong the QT interval. Most manufacturers advise avoiding the... |
| Osilodrostat | SEVERE | Both Erythromycin and Osilodrostat prolong the QT interval. Most manufacturers advise avoiding th... |
| Osimertinib | SEVERE | Both Erythromycin and Osimertinib prolong the QT interval. Most manufacturers advise avoiding the... |
| Ozanimod | SEVERE | Ozanimod might increase the risk of QT-prolongation when given with Erythromycin. Manufacturer ad... |
| Paliperidone | SEVERE | Both Erythromycin and Paliperidone prolong the QT interval. Most manufacturers advise avoiding th... |
| Palonosetron | SEVERE | Palonosetron is predicted to increase the risk of QT-prolongation when given with Erythromycin. M... |
| Panobinostat | SEVERE | Both Erythromycin and Panobinostat prolong the QT interval. Most manufacturers advise avoiding th... |
| Pasireotide | SEVERE | Both Erythromycin and Pasireotide prolong the QT interval. Most manufacturers advise avoiding the... |
| Pazopanib | SEVERE | Both Erythromycin and Pazopanib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Pemigatinib | SEVERE | Erythromycin is predicted to increase the exposure to Pemigatinib. Manufacturer makes no recommen... |
| Pentamidine | SEVERE | Pentamidine (intravenous or intramuscular) might increase the risk of QT-prolongation when given ... |
| Pimozide | SEVERE | Erythromycin is predicted to increase the exposure to Pimozide. Manufacturer advises avoid. |
| Piperaquine | SEVERE | Erythromycin is predicted to increase the concentration of Piperaquine. Manufacturer advises caut... |
| Ponesimod | SEVERE | Ponesimod might increase the risk of QT-prolongation when given with Erythromycin. Manufacturer a... |
| Pravastatin | SEVERE | Erythromycin slightly increases the exposure to Pravastatin. Manufacturer advises caution. |
| Prednisolone | SEVERE | Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Promethazine | SEVERE | Both Erythromycin and Promethazine prolong the QT interval. Most manufacturers advise avoiding th... |
| Quinine | SEVERE | Both Erythromycin and Quinine prolong the QT interval. Most manufacturers advise avoiding the use... |
| Quizartinib | SEVERE | Both Erythromycin and Quizartinib prolong the QT interval. Most manufacturers advise avoiding the... |
| Ranolazine | SEVERE | Erythromycin is predicted to increase the exposure to Ranolazine. Manufacturer advises caution. |
| Ribociclib | SEVERE | Both Erythromycin and Ribociclib prolong the QT interval. Most manufacturers advise avoiding the ... |
| Rifabutin | SEVERE | Erythromycin is predicted to increase the concentration of Rifabutin and Rifabutin is predicted t... |
| Ritonavir | SEVERE | Ritonavir is predicted to increase the exposure to Erythromycin. Manufacturer advises caution and... |
| Salbutamol | SEVERE | Salbutamol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Salmeterol | SEVERE | Salmeterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Selpercatinib | SEVERE | Both Erythromycin and Selpercatinib prolong the QT interval. Most manufacturers advise avoiding t... |
| Selumetinib | SEVERE | Erythromycin is predicted to increase the exposure to Selumetinib. Manufacturer advises avoid or ... |
| Sevoflurane | SEVERE | Both Erythromycin and Sevoflurane prolong the QT interval. Most manufacturers advise avoiding the... |
| Simvastatin | SEVERE | Erythromycin markedly increases the exposure to Simvastatin. Manufacturer advises avoid. |
| Siponimod | SEVERE | Erythromycin is predicted to increase the exposure to Siponimod. Manufacturer advises avoid depen... |
| Sorafenib | SEVERE | Both Erythromycin and Sorafenib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Sotalol | SEVERE | Both Erythromycin and Sotalol prolong the QT interval. Most manufacturers advise avoiding the use... |
| Sunitinib | SEVERE | Both Erythromycin and Sunitinib prolong the QT interval. Most manufacturers advise avoiding the u... |
| Tacrolimus | SEVERE | Erythromycin increases the concentration of Tacrolimus. Manufacturer advises avoid. If concurrent... |
| Tadalafil | SEVERE | Erythromycin is predicted to increase the exposure to Tadalafil. Manufacturer advises caution. |
| Talazoparib | SEVERE | Erythromycin is predicted to slightly increase the exposure to Talazoparib. Manufacturer advises ... |
| Terbutaline | SEVERE | Terbutaline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poi... |
| Tetrabenazine | SEVERE | Both Erythromycin and Tetrabenazine prolong the QT interval. Most manufacturers advise avoiding t... |
| Tezacaftor | SEVERE | Erythromycin is predicted to increase the exposure to Tezacaftor. Manufacturer advises adjust dos... |
| Theophylline | SEVERE | Theophylline is predicted to cause hypokalaemia (potentially increasing the risk of torsade de po... |
| Tolterodine | SEVERE | Both Erythromycin and Tolterodine prolong the QT interval. Most manufacturers advise avoiding the... |
| Topotecan | SEVERE | Erythromycin is predicted to increase the exposure to Topotecan. Manufacturer advises monitor. |
| Torasemide | SEVERE | Torasemide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Toremifene | SEVERE | Both Erythromycin and Toremifene prolong the QT interval. Most manufacturers advise avoiding the ... |
| Triamcinolone | SEVERE | Triamcinolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de p... |
| Vamorolone | SEVERE | Vamorolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Vandetanib | SEVERE | Both Erythromycin and Vandetanib prolong the QT interval. Most manufacturers advise avoiding the ... |
| Vanzacaftor | SEVERE | Erythromycin is predicted to increase the exposure to Vanzacaftor. Manufacturer advises adjust do... |
| Vardenafil | SEVERE | Erythromycin is predicted to increase the exposure to Vardenafil. Manufacturer advises adjust dose. |
| Vemurafenib | SEVERE | Erythromycin is predicted to increase the exposure to Vemurafenib. Manufacturer makes no recommen... |
| Venetoclax | SEVERE | Erythromycin is predicted to increase the exposure to Venetoclax. Manufacturer advises avoid or a... |
| Verapamil | SEVERE | Erythromycin is predicted to increase the exposure to Verapamil. Manufacturer advises monitor. |
| Vernakalant | SEVERE | Both Erythromycin and Vernakalant prolong the QT interval. Most manufacturers advise avoiding the... |
| Vilanterol | SEVERE | Vilanterol is predicted to cause hypokalaemia (potentially increasing the risk of torsade de poin... |
| Vinblastine | SEVERE | Erythromycin is predicted to increase the exposure to Vinblastine. Manufacturer advises caution. |
| Vincristine | SEVERE | Erythromycin is predicted to increase the exposure to Vincristine. Manufacturer advises caution. |
| Vindesine | SEVERE | Erythromycin is predicted to increase the exposure to Vindesine. Manufacturer advises caution. |
| Vinorelbine | SEVERE | Erythromycin is predicted to increase the exposure to Vinorelbine. Manufacturer advises caution. |
| Voclosporin | SEVERE | Erythromycin is predicted to increase the exposure to Voclosporin. Manufacturer advises adjust Vo... |
| Voriconazole | SEVERE | Both Erythromycin and Voriconazole prolong the QT interval. Most manufacturers advise avoiding th... |
| Warfarin | SEVERE | Erythromycin increases the anticoagulant effect of Warfarin. Manufacturer advises monitor INR and... |
| Xipamide | SEVERE | Xipamide is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointe... |
| Zanubrutinib | SEVERE | Erythromycin is predicted to increase the exposure to Zanubrutinib. Manufacturer advises avoid or... |
| Abemaciclib | MODERATE | Erythromycin is predicted to increase the exposure to Abemaciclib. Manufacturer advises monitor. |
| Afatinib | MODERATE | Erythromycin is predicted to increase the exposure to Afatinib. Manufacturer advises separating a... |
| Alfentanil | MODERATE | Erythromycin is predicted to increase the exposure to Alfentanil. Manufacturer advises monitor an... |
| Aliskiren | MODERATE | Erythromycin is predicted to increase the exposure to Aliskiren. Manufacturer advises caution. |
| Amlodipine | MODERATE | Erythromycin is predicted to increase the exposure to Amlodipine. Manufacturer advises monitor an... |
| Apixaban | MODERATE | Erythromycin is predicted to increase the exposure to Apixaban. Manufacturer makes no recommendat... |
| Aprepitant | MODERATE | Erythromycin is predicted to increase the exposure to Aprepitant. Manufacturer advises caution. |
| Atogepant | MODERATE | Erythromycin is predicted to increase the exposure to Atogepant. Manufacturer advises adjust Atog... |
| Avanafil | MODERATE | Erythromycin is predicted to increase the exposure to Avanafil. Manufacturer advises adjust Avana... |
| Avapritinib | MODERATE | Erythromycin is predicted to increase the exposure to Avapritinib. Manufacturer advises avoid or ... |
| Axitinib | MODERATE | Erythromycin is predicted to increase the exposure to Axitinib. Manufacturer makes no recommendat... |
| Bictegravir | MODERATE | Erythromycin is predicted to increase the exposure to Bictegravir. Manufacturer advises use with ... |
| Brigatinib | MODERATE | Erythromycin is predicted to increase the exposure to Brigatinib. Manufacturer advises monitor. |
| Buprenorphine | MODERATE | Erythromycin is predicted to increase the exposure to Buprenorphine. Manufacturer advises monitor... |
| Buspirone | MODERATE | Erythromycin is predicted to increase the exposure to Buspirone. Manufacturer advises use with ca... |
| Cabazitaxel | MODERATE | Erythromycin is predicted to increase the exposure to Cabazitaxel. Manufacturer makes no recommen... |
| Capivasertib | MODERATE | Erythromycin is predicted to increase the exposure to Capivasertib. Manufacturer advises adjust d... |
| Cilostazol | MODERATE | Erythromycin slightly increases the exposure to Cilostazol. Manufacturer advises adjust Cilostazo... |
| Cimetidine | MODERATE | Cimetidine slightly increases the exposure to Erythromycin. Manufacturer makes no recommendation. |
| Cobicistat | MODERATE | Cobicistat is predicted to increase the concentration of Erythromycin. Manufacturer makes no reco... |
| Dabrafenib | MODERATE | Erythromycin is predicted to increase the exposure to Dabrafenib. Manufacturer makes no recommend... |
| Dapoxetine | MODERATE | Erythromycin is predicted to increase the exposure to Dapoxetine. Manufacturer advises adjust Dap... |
| Darifenacin | MODERATE | Erythromycin slightly increases the exposure to Darifenacin. Manufacturer advises caution. |
| Dienogest | MODERATE | Erythromycin is predicted to slightly increase the exposure to Dienogest. Manufacturer makes no r... |
| Edoxaban | MODERATE | Erythromycin slightly increases the exposure to Edoxaban. Manufacturer advises adjust Edoxaban dose. |
| Eletriptan | MODERATE | Erythromycin moderately increases the exposure to Eletriptan. Manufacturer advises avoid. |
| Erlotinib | MODERATE | Erythromycin is predicted to increase the exposure to Erlotinib. Manufacturer makes no recommenda... |
| Everolimus | MODERATE | Erythromycin is predicted to increase the concentration of Everolimus. Manufacturer advises avoid... |
| Fedratinib | MODERATE | Erythromycin is predicted to increase the exposure to Fedratinib. Manufacturer advises monitor an... |
| Felodipine | MODERATE | Erythromycin is predicted to increase the exposure to Felodipine. Manufacturer advises monitor an... |
| Fentanyl | MODERATE | Erythromycin is predicted to increase the exposure to Fentanyl. Manufacturer advises monitor and ... |
| Fidaxomicin | MODERATE | Erythromycin is predicted to increase the exposure to Fidaxomicin. Manufacturer advises avoid. |
| Gefitinib | MODERATE | Erythromycin is predicted to increase the exposure to Gefitinib. Manufacturer makes no recommenda... |
| Gilteritinib | MODERATE | Erythromycin is predicted to increase the exposure to Gilteritinib. Manufacturer advises caution ... |
| Guanfacine | MODERATE | Erythromycin is predicted to increase the concentration of Guanfacine. Manufacturer advises adjus... |
| Idelalisib | MODERATE | Erythromycin is predicted to increase the exposure to Idelalisib. Manufacturer advises monitor. |
| Imatinib | MODERATE | Erythromycin is predicted to increase the exposure to Imatinib. Manufacturer advises caution. |
| Irinotecan | MODERATE | Erythromycin is predicted to increase the exposure to the active metabolite of Irinotecan. Manufa... |
| Isavuconazole | MODERATE | Erythromycin is predicted to increase the exposure to Isavuconazole. Manufacturer makes no recomm... |
| Ivacaftor | MODERATE | Erythromycin is predicted to increase the exposure to Ivacaftor. Manufacturer advises adjust dose... |
| Lacidipine | MODERATE | Erythromycin is predicted to increase the exposure to Lacidipine. Manufacturer advises monitor an... |
| Larotrectinib | MODERATE | Erythromycin is predicted to increase the exposure to Larotrectinib. Manufacturer advises monitor... |
| Leniolisib | MODERATE | Erythromycin is predicted to increase the exposure to Leniolisib. Manufacturer advises avoid. |
| Lercanidipine | MODERATE | Erythromycin is predicted to increase the exposure to Lercanidipine. Manufacturer advises monitor... |
| Letermovir | MODERATE | Erythromycin is predicted to increase the concentration of Letermovir. Manufacturer advises caution. |
| Lidocaine | MODERATE | Erythromycin is predicted to increase the exposure to Lidocaine. Manufacturer makes no recommenda... |
| Lomitapide | MODERATE | Erythromycin is predicted to increase the exposure to Lomitapide. Manufacturer advises avoid. |
| Lumacaftor | MODERATE | Lumacaftor is predicted to decrease the exposure to Erythromycin. Manufacturer advises consider a... |
| Lurasidone | MODERATE | Erythromycin is predicted to increase the exposure to Lurasidone. Manufacturer advises adjust Lur... |
| Macitentan | MODERATE | Erythromycin is predicted to increase the exposure to Macitentan. Manufacturer advises caution de... |
| Mavacamten | MODERATE | Erythromycin is predicted to increase the exposure to Mavacamten. Manufacturer advises adjust dos... |
| Midostaurin | MODERATE | Erythromycin is predicted to increase the exposure to Midostaurin. Manufacturer makes no recommen... |
| Momelotinib | MODERATE | Erythromycin is predicted to increase the exposure to Momelotinib. Manufacturer advises caution o... |
| Nadolol | MODERATE | Erythromycin is predicted to increase the exposure to Nadolol. Manufacturer makes no recommendation. |
| Naldemedine | MODERATE | Erythromycin is predicted to increase the exposure to Naldemedine. Manufacturer advises monitor. |
| Naloxegol | MODERATE | Erythromycin is predicted to increase the exposure to Naloxegol. Manufacturer advises adjust Nalo... |
| Nevirapine | MODERATE | Erythromycin is predicted to increase the exposure to Nevirapine. Manufacturer makes no recommend... |
| Nicardipine | MODERATE | Erythromycin is predicted to increase the exposure to Nicardipine. Manufacturer advises monitor a... |
| Nifedipine | MODERATE | Erythromycin is predicted to increase the exposure to Nifedipine. Manufacturer advises monitor an... |
| Nimodipine | MODERATE | Erythromycin is predicted to increase the exposure to Nimodipine. Manufacturer advises monitor an... |
| Nintedanib | MODERATE | Erythromycin is predicted to increase the exposure to Nintedanib. Manufacturer advises monitor. |
| Nirmatrelvir | MODERATE | Nirmatrelvir boosted with ritonavir is predicted to increase the concentration of Erythromycin. M... |
| Olaparib | MODERATE | Erythromycin is predicted to increase the exposure to Olaparib. Manufacturer advises avoid or adj... |
| Omaveloxolone | MODERATE | Erythromycin is predicted to increase the exposure to Omaveloxolone. Manufacturer advises avoid o... |
| Oxycodone | MODERATE | Erythromycin is predicted to increase the exposure to Oxycodone. Manufacturer advises monitor and... |
| Paclitaxel | MODERATE | Erythromycin is predicted to increase the exposure to Paclitaxel. Manufacturer advises caution. |
| Pibrentasvir | MODERATE | Erythromycin is predicted to increase the exposure to Pibrentasvir. Manufacturer makes no recomme... |
| Ponatinib | MODERATE | Erythromycin is predicted to increase the exposure to Ponatinib. Manufacturer advises caution. |
| Pralsetinib | MODERATE | Erythromycin is predicted to increase the exposure to Pralsetinib. Manufacturer makes no recommen... |
| Propafenone | MODERATE | Erythromycin is predicted to increase the exposure to Propafenone. Manufacturer advises monitor a... |
| Quetiapine | MODERATE | Erythromycin is predicted to increase the exposure to Quetiapine. Manufacturer advises avoid. |
| Regorafenib | MODERATE | Erythromycin is predicted to increase the exposure to Regorafenib. Manufacturer makes no recommen... |
| Relugolix | MODERATE | Erythromycin is predicted to increase the exposure to Relugolix. Manufacturer advises avoid or ta... |
| Rimegepant | MODERATE | Erythromycin is predicted to increase the exposure to Rimegepant. Manufacturer advises avoid anot... |
| Ripretinib | MODERATE | Erythromycin is predicted to increase the exposure to Ripretinib. Manufacturer advises monitor. |
| Rivaroxaban | MODERATE | Erythromycin slightly increases the exposure to Rivaroxaban. Manufacturer advises caution in rena... |
| Rupatadine | MODERATE | Erythromycin is predicted to increase the exposure to Rupatadine. Manufacturer advises avoid. |
| Sertraline | MODERATE | Erythromycin is predicted to increase the exposure to Sertraline. Manufacturer makes no recommend... |
| Sildenafil | MODERATE | Erythromycin is predicted to increase the exposure to Sildenafil. Manufacturer advises monitor or... |
| Sirolimus | MODERATE | Erythromycin increases the concentration of Sirolimus. Manufacturer advises monitor and adjust dose. |
| Sparsentan | MODERATE | Erythromycin is predicted to increase the exposure to Sparsentan. Manufacturer advises caution. |
| Sufentanil | MODERATE | Erythromycin is predicted to increase the exposure to Sufentanil. Manufacturer makes no recommend... |
| Tamsulosin | MODERATE | Erythromycin is predicted to increase the exposure to Tamsulosin. Manufacturer advises caution. |
| Temsirolimus | MODERATE | Erythromycin is predicted to increase the concentration of Temsirolimus. Manufacturer advises use... |
| Tofacitinib | MODERATE | Erythromycin given with a potent CYP2C19 inhibitor is predicted to increase the exposure to Tofac... |
| Tolvaptan | MODERATE | Erythromycin is predicted to increase the exposure to Tolvaptan. Manufacturer advises caution or ... |
| Trametinib | MODERATE | Erythromycin is predicted to increase the concentration of Trametinib. Manufacturer advises caution. |
| Trazodone | MODERATE | Erythromycin is predicted to increase the exposure to Trazodone. Manufacturer makes no recommenda... |
| Ulipristal | MODERATE | Erythromycin moderately increases the exposure to Ulipristal. Manufacturer advises avoid when use... |
| Zopiclone | MODERATE | Erythromycin is predicted to increase the exposure to Zopiclone. Manufacturer advises adjust dose. |
| Dutasteride | MILD | Erythromycin is predicted to moderately increase the exposure to Dutasteride. Manufacturer advise... |
| Fesoterodine | MILD | Erythromycin is predicted to increase the exposure to Fesoterodine. Manufacturer advises adjust F... |
| Ruxolitinib | MILD | Erythromycin slightly increases the exposure to Ruxolitinib. Manufacturer advises monitor adverse... |
| Saxagliptin | MILD | Erythromycin is predicted to increase the exposure to Saxagliptin. Manufacturer makes no recommen... |
| Tigecycline | MILD | Erythromycin might increase the exposure to Tigecycline. Manufacturer makes no recommendation. |
Check Erythromycin against your patient's full medication list
InteractRx checks all drug combinations at once — built for GP surgery pharmacists.
Use the Free Checker